Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apo2L/TRAIL plus rituximab in relapsed low-grade CD20-positive B-cell non-Hodgkin lymphoma after prior rituximab
2006-005552-33Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of dulanermin and rituximab in follicular lymphoma (FL) and mature B-cell lymphoma (2 arms), sponsored by Genentech. Primary endpoint: Objective response through follow-up month 12. Started Apr 2007; status: completed.
02
Drugs
dulanerminrituximab
03
Conditions
follicular lymphoma (FL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2006-005552-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005552-33.